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Abstract 
Sinus histiocytosis with massive lymphadenopathy (SHML) or Rosai-Dorfman disease 
(RDD) was first described as a distinct clinicopathological entity by Rosai and Dorfman in 
1969. SHML is commonly characterized by painless cervical lymphadenopathy, and its 
clinical course is generally benign and self-limiting. This disorder commonly involves the 
lymph nodes but may secondarily involve the skin. However, purely cutaneous disease 
without lymphadenopathy or internal organ involvement rarely occurs. In the absence of 
the massive lymphadenopathy that is characteristic of RDD, the diagnosis of purely 
cutaneous RDD may be complicated by the rare, nonspecific clinical appearance of skin 
lesions and the broad histopathological differential diagnosis of this disorder. A high 
level of suspicion of this disease on the part of the clinician or pathologist is often 
required. We present a case of cutaneous RDD associated with involvement of 
periodontal tissue. 
Case Report 
A 43-year-old man with a past medical history of Wolff-Parkinson-White syndrome presented with 
a 2-month history of an asymptomatic parieto-occipital skin lesion (a 1.5-cm red-yellow nodule). 
Superficial lymph nodes were not enlarged. The skin lesion was removed. The microscopic examination 
revealed numerous histiocytes with abundant pale cytoplasm invading the lymph sinuses. Occasionally, 
engulfed lymphocytes were noted in the cytoplasm of the histiocytes. Immunological staining showed 
that the invading histiocytes were positive for CD68 and S-100 protein and were negative for CD1a and 
CD20. These findings were consistent with the characteristics of Rosai-Dorfman disease (RDD). The 
leukocyte count was normal. No anemia or hypergammaglobulinemia was noted, and there was no 
reversal of CD4/CD8. The tests for hepatitis B surface antigen and antibodies to hepatitis C virus were 
negative. Neither antibodies to human T-cell leukemia virus 1 or human immunodeficiency virus nor  
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Epstein-Barr virus RNA were observed. Thoracic and abdominal CT showed a normal lung field with 
no mediastinal lymphadenopathy, no hepatosplenomegaly and no large lymphadenopathy. 
Hemophagocytic cells were absent in the bone marrow. The patient was eventually diagnosed with sinus 
histiocytosis with massive lymphadenopathy involving the skin. Because he also described a 1-year 
history of pain in his right inferior maxillary area, a positron emission tomography (PET) scan was 
performed, which showed fluorodeoxyglucose uptake in the right inferior maxillary area (SUV 8.7). 
Histological examination of the mucosal biopsy specimen showed large histiocytic cells with small 
round-to-oval nuclei, which were strongly positive for S-100 and CD68, without emperipolesis. The 
lesion was completely removed during surgery. A repeat PET was normal. The patient remained 
asymptomatic with no signs of recurrence at the 3-month follow-up. 
Discussion 
Sinus histiocytosis with massive lymphadenopathy (SHML) is a rare disorder that is 
characterized by non-malignant proliferation of distinctive histiocytic/phagocytic cells 
within lymph node sinuses and the lymphatic system in extranodal sites. This condition 
primarily affects children and young adults. In the literature, 423 cases of RDD have been 
reported [1]. 
Although SHML is relatively rare, purely cutaneous RDD is even less common, 
accounting for approximately 3% of SHML cases in one large study [2]. SHML skin 
lesions may be diverse and can be found in virtually any location, including the face, ears, 
trunk, extremities or genitalia [1, 3]. Several authors have suggested that cutaneous RDD 
is a distinct clinical entity because of its unique epidemiology and the lack of systemic 
involvement even with long-term follow-up [3–5]. The characteristics of nodal and purely 
cutaneous RDD are shown in table 1. 
Extranodal disease is documented in 30–40% of patients, and in some patients it 
presents without associated lymphadenopathy, which may develop later in the course of 
disease [1]. Extranodal involvement of at least one site is not uncommon, and it is rarely 
the initial and only manifestation of the disease. The most commonly affected extranodal 
sites include the skin and soft tissue, the upper respiratory tract and bone followed by the 
genitourinary tract, the lower respiratory tract, the oral cavity, the gastrointestinal tract 
[6], the orbit [7] and the testes. In cutaneous RDD, extranodal disease may also develop at 
other sites, e.g. the eye, most commonly leading to uveitis [8, 9]. Central nervous system 
involvement is very rare (<5%) [10]. 
Clinical laboratory findings include hematologic abnormalities, such as normocytic or 
microcytic anemia [1, 11] and polyclonal hypergammaglobulinemia (90%). Rarely, 
patients exhibit rheumatoid factor, antinuclear antibodies and a reversal of the CD4/CD8 
ratio among peripheral lymphocytes. Immunological abnormalities are found in a 
significant number of patients and often lead to a clinically unfavorable disease course. 
Consistent serologic findings are lacking, although antibodies to pathogens, including 
EBV and human herpesvirus (HHV-6), have been reported [12]. A small subset of 
patients also has concurrent neoplasia, including non-Hodgkin lymphoma, other 
histiocytic proliferations, myeloma, melanoma and carcinoma. In the case presented 
herein, there was no relation to EBV, HIV or HHV-6 infection, or to any other neoplasia. 
The hallmark of the SHML histiocyte is the presence of a variable number of intact 
lymphocytes within the cytoplasm of the cell, which is a phenomenon referred to as 
lymphophagocytosis or emperipolesis [1]. The histological differential diagnosis includes  
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Langerhans cell histiocytosis, histiocytic sarcoma, storage disorders such as Gaucher’s 
disease, classical Hodgkin’s lymphoma, metastatic melanoma and carcinoma, as well as 
infections caused by Histoplasma and mycobacteria that involve the lymph nodes. 
The most useful immunohistological markers for SHML histiocytes are the S-100 
protein and the pan-macrophage antigens (CD86, CD14, CD15 and CD64). Whereas 
Langerhans cells positively stain for the S-100 protein and CD1a, only rare CD1a-positive 
cells are found in SHLM. 
The clinical course of SHML is characterized by spontaneous resolution in most cases, 
especially in those presenting with localized lymph node involvement. Sometimes, there 
are episodes of exacerbation alternating with periods of remission that continue for many 
years. Persistence of lymphadenopathy or progression to widespread dissemination may 
occur, particularly in SHML that involves the kidneys, the lower respiratory tract or the 
liver with associated immunological dysfunction. The reported mortality rate is 7%, with 
many patients who have a fatal outcome having concomitant immune dysfunction [13]. 
The pathogenesis of this disease is poorly understood, although some researchers have 
suggested that either infection or immunodeficiency might play a role [14]. Recently, 
cases of SHML associated with the autoimmune lymphoproliferative syndrome have been 
described [15]. 
The disease is self-limiting in most cases. In a recent review of treatment strategies for 
SHML, 50% of patients (40/80) did not require any treatment. Patients given antibiotics 
or anti-tuberculous drugs showed no response. Steroid therapy resulted in a reduction in 
lymphadenopathy and associated fever. Only 2 of a total of 12 patients achieved complete 
and durable remission after treatment with methotrexate. High-dose interferon-α was 
given to 1 patient, which resulted in long-term remission [16]. In a recent report, the use 
of the purine analogue 2-chlorodeoxyadenosine was found to be of clinical utility in these 
cases [17]. The ideal treatment for SHML has not yet been determined. Cutaneous lesions 
have been reported to respond to radiotherapy [4], cryotherapy, excision [4, 5], topical 
and oral corticosteroids [4], and high-dose thalidomide [5]. 
The diagnosis of RDD should be considered in any atypical chronic inflammatory 
lesion with a histiocytic component involving multiple organ systems, especially the skin. 
In our case, the inflammatory lesion was localized to the maxillary area. 
Immunohistochemical stains for the S-100 protein should be performed in these cases. To 
our knowledge, this is the first case reported with such characteristics. 
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Table 1. Differential characteristics of nodal and purely cutaneous Rosai-Dorfman disease 
Characteristics  Nodal Rosai-Dorfman  Purely cutaneous Rosai-Dorfman 
Frequency 60–70%  3% 
Predominant sex  male  female 
Age  20.6 years  43.7 years 
Race no  race  predominant  Asian/white 
Presenting symptoms  painless lymphadenopathy  cutaneous lesion 
General symptoms  typically fever, malaise,  
night sweats 
usually none 
Nodal involvement  yes  no 
Involved area  cervical region (90%)  face, ears, trunk, extremities, genitalia 
Biopsy 
Emperipolesis 
Fibrosis 
S-100 
CD1a 
 
very common 
not very common 
positive 
negative most times 
 
not very common 
very common 
positive 
usually negative 
Treatment observation 
steroids 
chemotherapy 
methotrexate 
alkylating agents 
high doses of interferon-α 
observation 
steroids (oral or local) 
radiotherapy 
cryotherapy 
surgery 
high doses of thalidomide 
 
 
 
References 
1 Foucar E, Rosai J, Dorfman R: Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): 
review of the entity. Semin Diagn Pathol 1990;7:19–73. 
2 Chuah KL, Tan PH, Hwang SG, Ong BH: Cutaneous Rosai-Dorfman disease – a cytopathologic review of 2 
cases. Singapore Med J 2000;41:122–125. 
3 Wang KH, Chen WY, Liu HN, Huang CC, Lee WR, Hu CH: Cutaneous Rosai-Dorfman disease: 
clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol 2006;154:277–
286. 
4 Brenn T, Calonje E, Granter SR, et al: Cutaneous Rosai-Dorfman disease is a distinct clinical entity. Am J 
Dermatopathol 2002;24:385–391. 
5 Lu C, Kuo T, Wong W, Hong H: Clinical and histopathologic spectrum of cutaneous Rosai-Dorfman disease in 
Taiwan. J Am Acad Dermatol 2004;51:931–939. 
6 Alatassi H, Ray MB, Galandiuk S, Sahoo S: Rosai-Dorfman disease of the gastrointestinal tract: report of a case 
and review of the literature. Int J Surg Pathol 2006;14:95–99. 
7 Wang E, Anzai Y, Paulino A, Wong J: Rosai-Dorfman disease presenting with isolated bilateral orbital masses: 
report of two cases. Am J Neuroradiol 2001;22:1386–1388. 
8 Salim A, Williamson M, Barker F, Hughes J: Steroid responsive cutaneous Rosai-Dorfman disease associated 
with uveitis and hypothyroidism. Clin Exp Dermatol 2002;27:277–279. 
9 Kroumpouzos G, Demierre MF: Cutaneous Rosai-Dorfman disease: histopathological presentation as 
inflammatory pseudotumor. A literature review. Acta Derm Venereol 2002;82:292–296. 
10 Wu M, Anderson AE, Kahn LB: A report of intracranial Rosai-Dorfman disease with literature review. Ann 
Diagn Pathol 2001;5:96–102. 
11 Grabczynska SA, Toh CT, Francis N, Costello C, Bunker CB: Rosai-Dorfman disease complicated by 
autoimmune haemolytic anaemia: case report and review of a multisystem disease with cutaneous infiltrates. 
Br J Dermatol 2001;145:323–326.  
Case Rep Oncol 2011;4:96–100 
DOI: 10.1159/000324760 
Published online: 
February 16, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
100
12 Luppi M, Barozzi P, Garber R, et al: expression of human herpesvirus-6 antigens in benign and malignant 
lymphoproliferative diseases. Am J Pathol 1998;153:815–823. 
13 Komp DM: The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). 
Semin Diagn Pathol 1990;7:83–86. 
14 Alvarez Alegret R, Martinez Tello A, Ramirez T, Gallego P, Martinez D, Garcia Julian G: Sinus histiocytosis 
with massive lymphadenopathy (Rosai-Dorfman disease). Diagnosis with fine-needle aspiration in a case with 
nodal or nasal involvement. Diagn Cytopatol 1995;13:333–335. 
15 Maric I, Pittaluga S, Dale J, Straus SE, Jaffe ES: Sinus histiocytosis with massive lympadenopathy in patients 
with autoimmune lymphoproliferative syndrome. Mode Pathol 2004;17:258A. 
16 Pulsoni A, Anghel G, Falcucci P, et al: Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-
Dorfman disease): report of a case and literature review. Am J Hematol 2002;69:67–71. 
17 Rodríguez-Galindo C, Helton KJ, Sanchez ND, Rieman M, Jeng M, Wang W: Extranodal Rosai-Dorfman 
disease in children. J Pediatr Hematol Oncol 2004;26:19–24. 